Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 11/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | MERTK | Q12866 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL863847 | 1.00 | PIK3CD (0.34) | PIK3CDPIK3CGPIK3CAPIK3CBPIK3R2 | |
| SCHEMBL864012 | 0.85 | PIK3CD (0.48) | PIK3CDPIK3CGPIK3CAPIK3CBEGFR | |
| SCHEMBL864011 | 0.85 | PIK3CD (0.48) | PIK3CDPIK3CGPIK3CAPIK3CBEGFR | |
| SCHEMBL863647 | 0.82 | PIK3CD (0.50) | PIK3CDPIK3CGPIK3CAPIK3CBAXL | |
| SCHEMBL863646 | 0.82 | PIK3CD (0.50) | PIK3CDPIK3CGPIK3CAPIK3CBAXL | |
| SCHEMBL14482164 | 0.81 | PIK3CD (0.35) | PIK3CDPIK3CGPIK3CAPIK3CBPIK3R2 | |
| SCHEMBL15184779 | 0.80 | MAPT (0.35) | — | |
| SCHEMBL14482222 | 0.79 | PIK3CD (0.33) | PIK3CDPIK3CGPIK3CAPIK3CBAXL | |
| SCHEMBL14482213 | 0.78 | NOTUM (0.34) | PIK3CDPIK3CGPIK3CAPIK3CBEGFR | |
| SCHEMBL863994 | 0.78 | CHRM4 (0.37) | PIK3CDPIK3CGPIK3CAPIK3CBPIK3R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2396315-B1 | QUINOLINE DERIVATIVES AS PI3K KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2016-08-31 | — | — | EP | disclosed |
| US-8513284-B2 | Fused pyridine and pyrazine derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2013-08-20 | — | — | US | disclosed |
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | PDPK1, PDXK, PIK3CA | PIK3CD 14/4885PIK3CG 21/4885PIK3CA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.